HC Wainwright Issues Positive Forecast for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Stock analysts at HC Wainwright raised their Q1 2025 earnings per share (EPS) estimates for Protara Therapeutics in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.53) per share for the quarter, up from their previous forecast of ($0.57). HC Wainwright has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($2.74) EPS, FY2027 earnings at ($2.75) EPS and FY2028 earnings at ($1.75) EPS.

Separately, Guggenheim reissued a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th.

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $4.02 on Monday. The firm has a 50-day simple moving average of $4.56 and a 200-day simple moving average of $3.42. Protara Therapeutics has a one year low of $1.60 and a one year high of $10.48. The firm has a market cap of $82.93 million, a P/E ratio of -1.43 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09.

Institutional Trading of Protara Therapeutics

A number of institutional investors have recently made changes to their positions in the business. RA Capital Management L.P. increased its position in Protara Therapeutics by 78.9% during the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after buying an additional 1,500,000 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Protara Therapeutics during the fourth quarter valued at about $11,938,000. Adage Capital Partners GP L.L.C. purchased a new position in shares of Protara Therapeutics in the 4th quarter valued at approximately $11,880,000. Toronto Dominion Bank acquired a new stake in Protara Therapeutics in the 4th quarter worth approximately $11,030,000. Finally, Blackstone Inc. acquired a new stake in Protara Therapeutics in the 4th quarter worth approximately $8,870,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.